If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
In pharmacology, relative bioavailability measures the bioavailability (estimated as the AUC) of a formulation (A) of a certain drug when compared with another formulation (B) of the same drug, usually an established standard, or through administration via a different route. When the standard consists of intravenously administered drug, this is known as absolute bioavailability (see above). F r e l = 100 ⋅ A U C A ⋅ D B A U C B ⋅ D A {\displaystyle F_{\mathrm {rel} }=100\cdot {\frac {AUC_{\mathrm {A} }\cdot D_{\mathrm {B} }}{AUC_{\mathrm {B} }\cdot D_{\mathrm {A} }}}}
Uranium-236 has a half-life of about 23 million years; and is neither fissile with thermal neutrons, nor very good fertile material, but is generally considered a nuisance and long-lived radioactive waste. It is found in spent nuclear fuel and in the reprocessed uranium made from spent nuclear fuel.
Short-acting insulin analogues are modified forms of recombinant human insulin designed to enhance subcutaneous absorption and accelerate glycemic control. In standard insulin formulations, regular insulin monomers naturally aggregate into hexamers, a configuration that delays absorption and prolongs the onset of action. Before entering the bloodstream, these hexamers must dissociate into dimers and then monomers, which slows their availability for glucose regulation. To address this limitation, insulin analogues have been engineered to maintain a monomeric or dimeric configuration, allowing for faster absorption and reducing the time to onset to approximately 5 to 15 minutes. Insulin lispro, insulin aspart, and insulin glulisine are the most widely used short-acting insulin analogues. These formulations are structurally identical to human insulin, except for amino acid substitutions at one or two positions, which modify their stability and absorption characteristics. Insulin lispro, which was first approved in 1996 and marketed as Humalog among others, works by reversing the final lysine and proline residues on the C-terminal end of the B-chain. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. Clinical studies have demonstrated that the use of insulin lispro instead of regular insulin can reduce hypoglycemia incidence and improve glycemic control.
== Lifestyle and nutrition == Regular physical activity, particularly weight-bearing and resistance exercises, has been shown to improve bone density and reduce the likelihood of fractures. While placing weight-bearing stress on these bones, it will signal the body to start strengthening and it will help stimulate bone growth to make the bones stronger over time. Adequate intake of calcium and vitamin D is essential for bone health. The National Osteoporosis Foundation recommends a daily calcium intake of 1,000 mg for men aged 50-70 and 1,200 mg for women aged 51 and older and men aged 71 and older. For vitamin D, a daily intake of 800-1,000 IU is recommended for adults aged 50 and older.
== Overview == When an elastic material is deformed due to an external force, it experiences internal resistance to the deformation so that it is restored to its original state if the external force is no longer applied. There are various elastic moduli, such as Young's modulus, the shear modulus, and the bulk modulus, all of which are measures of the inherent elastic properties of a material as a resistance to deformation under an applied load. The various moduli each apply to different kinds of deformation. For instance, Young's modulus applies to extension or ←compression of a body, whereas the shear modulus applies to its shear. Young's modulus and shear modulus only apply to solids, whereas the bulk modulus applies to solids, liquids, and gases. The elasticity of materials is described by a stress–strain curve, which shows the relation between stress (the average restorative internal force per unit area) and strain (the relative deformation). The curve is generally nonlinear, but it can (by use of a Taylor series) be approximated as linear for sufficiently small deformations (in which higher-order terms are negligible). If the material is isotropic, the linearized stress–strain relationship is called Hooke's law, which is often presumed to apply up to the elastic limit for most metals or crystalline materials whereas nonlinear elasticity is generally required to model large deformations of rubbery materials even in the elastic range.
Sources: en.wikipedia.org
Whether synthesized in the skin or ingested, vitamin D is hydroxylated in the liver at position 25 (upper right of the molecule) to form the prohormone calcifediol, also referred to as 25(OH)D). This reaction is catalyzed by the microsomal enzyme vitamin D 25-hydroxylase, the product of the CYP2R1 human gene. Once made, the product is released into the blood where it is bound to vitamin D-binding protein. Calcifediol is transported to the proximal tubules of the kidneys, where it is hydroxylated at the 1-α position (lower right of the molecule) to form calcitriol (1,25-dihydroxycalciferol, also referred to as 1,25(OH)2D). The conversion of calcifediol to calcitriol is catalyzed by the enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase, which is the product of the CYP27B1 human gene. The activity of CYP27B1 is increased by parathyroid hormone and also by low plasma calcium or phosphate. Following the final metabolic step in the kidney, calcitriol is released into circulation. By binding to vitamin D-binding protein, calcitriol is transported throughout the body. In addition to the kidneys, calcitriol is also synthesized by certain other cells, including monocyte-macrophages in the immune system. When synthesized by monocyte-macrophages, calcitriol acts locally as a cytokine, modulating body defenses against microbial invaders by stimulating the innate immune system.
Cárdenas' capture in 2003 and extradition in 2007 weakened the cartel, but the resulting fragmentation and the independence of Los Zetas intensified violence in the context of the drug war, leaving a lasting legacy of conflict in Mexico in the decades that followed. Following the capture of Osiel Cárdenas Guillén in 2003 and his extradition in 2007, leadership fell to Jorge Eduardo Costilla Sánchez, a key figure in the Gulf Cartel, who led the criminal organization until 2012. Internal dynamics and rivalries, especially with Los Zetas, defined his era. The pursuit of Joaquín "El Chapo" Guzmán from 2001 to 2014 is a pivotal case in the context of the 21st-century global war on drugs, as it exemplifies the challenges of combating sophisticated transnational criminal organizations. Guzmán, as the leader of the Sinaloa Cartel, orchestrated one of the most powerful drug trafficking networks, responsible for smuggling vast quantities of narcotics into the United States and Europe, generating billions in illicit revenue. His 2001 escape from a high-security Mexican prison and subsequent evasion until his 2014 capture highlighted the systemic corruption, institutional weaknesses, and cross-border complexities that hinder effective counter-narcotics strategies. The operation to apprehend him, involving Mexican authorities and U.S.
== Measurement == Though relative atomic masses are defined for neutral atoms, they are measured (by mass spectrometry) for ions: hence, the measured values must be corrected for the mass of the electrons that were removed to form the ions, and also for the mass equivalent of the electron binding energy, Eb/muc2. The total binding energy of the six electrons in a carbon-12 atom is 1030.1089 eV = 1.6504163×10−16 J: Eb/muc2 = 1.1058674×10−6, or about one part in 10 million of the mass of the atom. Before the 2019 revision of the SI, experiments were aimed to determine the value of the Avogadro constant for finding the value of the unified atomic mass unit.
The chemical structure of myristicin is similar to some amphetamines, and it may be capable of producing psychoactive effects. Normal levels of intake of myristicin from spices in food is unlikely to cause these effects. Myristicin can be used in the chemical synthesis of amphetamine derivatives such as the designer drug MMDMA that is similar in chemical structure and effect to MDMA. Out of the common spices that contain myristicin, nutmeg has a high relative concentration of the compound, and therefore is used to exploit the effects of myristicin. At a minimum dose of about 5 grams of nutmeg powder, symptoms of nutmeg intoxication can begin to emerge. Nutmeg intoxication may produce dizziness, drowsiness, and confusion, although in higher amounts, it may have effects similar to deliriants. The effects of nutmeg consumed in large doses may involve myristicin: 1–7 hours following ingestion, symptoms include disorientation, giddiness, stupor, and stimulation of the central nervous system leading to euphoria. Also occurring are mild to intense hallucinations (similar to those induced by deliriants: walls and ceiling glitching or breathing), disorientation to time and surroundings, dissociation, feelings of levitation, loss of consciousness, tachycardia, weak pulse, anxiety, and hypertension. Symptoms of nutmeg intoxication further include nausea, abdominal pain, vomiting, minor to severe muscle spasms (severe in extreme overdose), headache, dryness of mouth, mydriasis or miosis, hypotension, shock, and potentially death.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.